Clinical research for intramedullary spinal cord metastases

doi:10.3760/cma.j.issn.1673-422X.2014.02.014

Abstract

Abstract: Intramedullary spinal cord metastases (ISCM) is infrequently observed clinically, spreading mainly from lung cancer and breast cancer, and they can occur in any location of the spinal cord, with weakness and sensory alteration or loss presenting in most patients. Magnetic resonance imaging is the most effective and noninvasive technique for diagnosis until now. The optimal treatment for ISCM remains controversial, and surgical excision and radiotherapy are the most common recommendations. Regardless of the treatment, its prognosis is poor now, with the median survival time 4-9 months.

Key words: Spinal cord neoplasms, Neoplasm metastasis, Therapy, Clinical feature

Li Ruijian, Yu Liang. Clinical research for intramedullary spinal cord metastases[J]. Journal of International Oncology, 2014, 41(2): 124-126.

References

［1］ Kalayci M, Caˇgavi F, Gül S, et al. Intramedullary spinal cord metastases: diagnosis and treatment—an illustrated review［J］. Acta Neurochir (Wien), 2004, 146(12): 1347-1354. ［2］ Kalita O. Current insights into surgery for intramedullary spinal cord metastases: a literature review［J］. Int J Surg Oncol, 2011, 2011: 989506. ［3］ Hrabalek L, Kalita O, Studentova H, et al. Intramedullary spinal cord and cauda equina metastasis of breast carcinoma: case report［J］. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2010, 154(2): 175177. ［4］ Sung WS, Sung MJ, Chan JH, et al. Intramedullary spinal cord metastases: a 20year institutional experience with a comprehensive literature review［J］. World Neurosurg, 2013, 79(34): 576584. ［5］ Rostami R, Safarpour D, Tavassoli FA, et al. Intramedullary metastasis in breast cancer—a comprehensive literature review［J］. J Neurol Sci, 2013, 332(12): 1620. ［6］ DamHieu P, Seizeur R, Mineo JF, et al. Retrospective study of 19 patients with intramedullary spinal cord metastasis［J］. Clin Neurol Neurosurg, 2009, 111(1): 1017. ［7］ Lee SS, Kim MK, Sym SJ, et al. Intramedullary spinal cord metastases: a singleinstitution experience［J］. J Neurooncol, 2007, 84(1): 8589. ［8］ Ishii T, Terao T, Komine K, et al. Intramedullary spinal cord metastases of malignant melanoma: an autopsy case report and review of the literature［J］. Clin Neuropathol, 2010, 29(5): 334340. ［9］ Veeravagu A, Lieberson RE, Mener A, et al. CyberKnife stereotactic radiosurgery for the treatment of intramedullary spinal cord metastases［J］. J Clin Neurosci, 2012, 19(9): 12731277. ［10］ Conill C, Marruecos J, Verger E, et al. Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer［J］. Clin Transl Oncol, 2007, 9(3): 172176. ［11］ Hrabalek L. Intramedullary spinal cord metastases: review of the literature［J］. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2010, 154(2): 117122. ［12］ DoDai DD, Brooks MK, Goldkamp A, et al. Magnetic resonance imaging of intramedullary spinal cord lesions: a pictorial review［J］. Curr Probl Diagn Radiol, 2010, 39(4): 160185. ［13］ Nguyen NC, Sayed MM, Taalab K, et al. Spinal cord metastases from lung cancer: detection with F18 FDG PET/CT［J］. Clin Nucl Med, 2008, 33(5): 356358. ［14］ Gilardi L, Vassallo S, Colandrea M, et al. Intramedullary spinal cord metastases from breast cancer: detection with (18)FFDG PET/CT［J］. Ecancermedicalscience, 2013, 7: 329. ［15］ Hashii H, Mizumoto M, Kanemoto A, et al. Radiotherapy for patients with symptomatic intramedullary spinal cord metastasis［J］. J Radiat Res, 2011, 52(5): 641645. ［16］ Wilson DA, Fusco DJ, Uschold TD, et al. Survival and functional outcome after surgical resection of intramedullary spinal cord metastases［J］. World Neurosurg, 2012, 77(2): 370374. ［17］ Hoover JM, Krauss WE, Lanzino G. Intradural spinal metastases: a surgical series of 15 patients［J］. Acta Neurochir (Wien), 2012, 154(5): 871877. ［18］ Belaid I, Jlassi H, Debbiche G, et al. Lung adenocarcinoma with intramedullary spinal cord metastasis: a case report and review of the literature［J］. Rev Pneumol Clin, 2013, 69(3): 149151. ［19］ Kodama M, Kawaguchi H, Komoto Y, et al. Coexistent intramedullary spinal cord and choroidal metastases in ovarian cancer［J］. J Obstet Gynaecol Res, 2010, 36(1): 199203. ［20］ Choi HC, Yoon do H, Kim SC, et al. Two separate episodes of intramedullary spinal cord metastasis in a single patient with breast cancer［J］. J Korean Neurosurg Soc, 2010, 48(2): 162165.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.